Loading company…
Transmutex develops nuclear engineering technologies to reduce nuclear waste and produce energy and medical isotopes.
Transmutex develops accelerator-based nuclear technologies for energy production, reducing nuclear waste, and producing medical isotopes. Founded in 2019, the company is based in Geneva, Switzerland, and led by CEO Franklin Servan-Schreiber. It received CHF 4.3 million in grant funding from the U.S. Department of Energy in January 2025 to advance work on reducing nuclear waste volume and half-life.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in